Remove sign-up
article thumbnail

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

pharmaphorum

Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships

Pharma 101
article thumbnail

Owkin signs up another pharma partner for its AI platform

pharmaphorum

Owkin signs up another pharma partner for its AI platform Phil.Taylor Tue, 17/10/2023 - 10:29 Bookmark this

Pharma 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sandoz, nearing Novartis split, signs up to commercialize Samsung Bioepis' Stelara biosimiliar

Fierce Pharma

After plotting a course to grow by leveraging its biosimilar expertise, Sandoz has inked a deal to get involved in one of the industry's next major biosim debuts. | The blockbuster inflammatory med's patents begin to expire this year, leaving biosimilar makers scrambling for a piece of the large market.

Marketing 243
article thumbnail

Celltrion signs up to support Rani’s oral biosimilar copy of J&J’s Stelara, lands right of first negotiation

Fierce Pharma

Celltrion signs up to support Rani’s oral biosimilar copy of J&J’s Stelara, lands right of first negotiation. Tue, 01/10/2023 - 10:24.

130
130
article thumbnail

Sanofi leans on COPD as 'next major growth pillar' for its immunology star Dupixent: CEO

Fierce Pharma

Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down.

169
169
article thumbnail

Genentech signs nanoparticle deal worth up to $644m with GenEdit

Pharmaceutical Technology

Genentech will utilise GenEdit’s non-viral polymer nanoparticles for gene therapy delivery in autoimmune diseases.

96
article thumbnail

ImmunoGen signs loan agreement with Pharmakon for up to $175m

Pharmaceutical Technology

US-based biotechnology company ImmunoGen has signed a term loan financing facility worth up to $175m with the entities of Pharmakon Advisors. ImmunoGen will use the proceeds from the agreement to support its growth trajectory and bolster its balance sheet. The company will receive the loan facility in two tranches.

Sales 52